Patents Assigned to Research Enterprises, Inc.
  • Patent number: 10821079
    Abstract: The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: November 3, 2020
    Assignee: Cognitive Research Enterprises, Inc.
    Inventors: Daniel L. Alkon, Thomas J. Nelson
  • Publication number: 20200331875
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 22, 2020
    Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. NELSON, Daniel L. ALKON
  • Patent number: 10696644
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: June 30, 2020
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Publication number: 20190365706
    Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Application
    Filed: July 16, 2019
    Publication date: December 5, 2019
    Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventor: Daniel L. ALKON
  • Publication number: 20190270715
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturted fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono and polyunsaturated fatty acids.
    Type: Application
    Filed: May 1, 2019
    Publication date: September 5, 2019
    Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. NELSON, Daniel L. ALKON
  • Patent number: 10323011
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: June 18, 2019
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Patent number: 10137106
    Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 27, 2018
    Assignee: Cognitive Research Enterprises, Inc.
    Inventor: Daniel L. Alkon
  • Publication number: 20180311209
    Abstract: Dosing regimens and methods are disclosed for upregulating on protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Application
    Filed: October 8, 2016
    Publication date: November 1, 2018
    Applicant: Cognitive Research Enterprises, Inc.
    Inventor: Daniel L. ALKON
  • Patent number: 9974832
    Abstract: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: May 22, 2018
    Assignee: Cognitive Research Enterprises, Inc.
    Inventors: Ofer Zohar, Daniel L. Alkon
  • Patent number: 9597312
    Abstract: The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 21, 2017
    Assignee: Cognitive Research Enterprises, Inc.
    Inventors: Miao-kun Sun, Daniel L. Alkon
  • Patent number: 9539235
    Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 10, 2017
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC
    Inventors: Rene Etcheberrigaray, Daniel L. Alkon
  • Patent number: 6056311
    Abstract: An elongate board which produces increased lift when moved through a fluid such as air or water. The elongate board includes a main body with an opening in its central region. A plurality of transverse wing sections are mounted in tandem in the central opening along the longitudinal axis of the main body. Between each wing section is an open slot allowing the fluid to flow over the wing sections, creating a lifting force on the elongate board. The elongate board may be utilized in many different sports requiring the use of a ski or board, such as water skiing, snow skiing, surfboarding, snow boarding, and sky surfboarding.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: May 2, 2000
    Assignee: Dal Research Enterprises, Inc.
    Inventor: Kam Fong Leung
  • Patent number: 5519607
    Abstract: An automated health benefit processing system. The system includes a database and three processors. The database includes, for each geographic area and for each medical procedures for which a benefit is payable, the benefit payable to an insured if the procedure is prescribed and performed, a list of providers available to perform the designated procedure, and each provider's charge for performing the designated procedure. The first processor generates a treatment plan concerning the insured that specifies the identity of the insured and the medical procedures to be performed on the insured. The first processor also accesses the database to retrieve the information stored in the database under the medical procedures to be performed and to append this information to the treatment plan. The second processor generates a treatment record specifying the medical procedures actually performed by a provider and the provider's actual charge therefor.
    Type: Grant
    Filed: July 6, 1993
    Date of Patent: May 21, 1996
    Assignee: Research Enterprises, Inc.
    Inventor: Jack J. Tawil
  • Patent number: 5225976
    Abstract: An automated health benefit processing system. The system includes a database and three processors. The database includes, for each geographic area and for each medical procedures for which a benefit is payable, the benefit payable to an insured if the procedure is prescribed and performed, a list of providers available to perform the designated procedure, and each provider's charge for performing the designated procedure. The first processor generates a treatment plan concerning the insured that specifies the identity of the insured and the medical procedures to be performed on the insured. The first processor also accesses the database to retrieve the information stored in the database under the medical procedures to be performed and to append this information to the treatment plan. The second processor generates a treatment record specifying the medical procedures actually performed by a provider and the provider's actual charge therefor.
    Type: Grant
    Filed: March 12, 1991
    Date of Patent: July 6, 1993
    Assignee: Research Enterprises, Inc.
    Inventor: Jack J. Tawil